[go: up one dir, main page]

MA58087B1 - Nouveaux dérivés de méthylquinazolinone - Google Patents

Nouveaux dérivés de méthylquinazolinone

Info

Publication number
MA58087B1
MA58087B1 MA58087A MA58087A MA58087B1 MA 58087 B1 MA58087 B1 MA 58087B1 MA 58087 A MA58087 A MA 58087A MA 58087 A MA58087 A MA 58087A MA 58087 B1 MA58087 B1 MA 58087B1
Authority
MA
Morocco
Prior art keywords
methylquinazolinone
derivatives
new
compound
formula
Prior art date
Application number
MA58087A
Other languages
English (en)
Inventor
Daniel Hunziker
Cosimo Dolente
David Stephen HEWINGS
Daniela Krummenacher
Piergiorgio Francesco Tommaso PETTAZZONI
Juergen Wichmann
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA58087B1 publication Critical patent/MA58087B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Combines (AREA)
  • Harvester Elements (AREA)

Abstract

L'invention concerne un nouveau composé ayant la formule générale (I), ou un sel pharmaceutiquement acceptable de celui-ci. Le composé de formule (I) peut être utilisé en tant que médicament.
MA58087A 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone MA58087B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
EP20817377.3A EP4073065B1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de methylquinazolinone
PCT/EP2020/084976 WO2021116055A1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone

Publications (1)

Publication Number Publication Date
MA58087B1 true MA58087B1 (fr) 2025-04-30

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58087A MA58087B1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone

Country Status (29)

Country Link
US (2) US12116349B2 (fr)
EP (2) EP4483882A3 (fr)
JP (2) JP7108146B2 (fr)
KR (1) KR102836833B1 (fr)
CN (2) CN118791472A (fr)
AR (1) AR122351A1 (fr)
AU (1) AU2020403443B2 (fr)
CL (1) CL2022001529A1 (fr)
CO (1) CO2022008968A2 (fr)
CR (1) CR20220251A (fr)
DK (1) DK4073065T3 (fr)
ES (1) ES3023264T3 (fr)
FI (1) FI4073065T3 (fr)
HR (1) HRP20250418T1 (fr)
HU (1) HUE071148T2 (fr)
IL (2) IL292161B2 (fr)
LT (1) LT4073065T (fr)
MA (1) MA58087B1 (fr)
MX (1) MX2022006783A (fr)
PE (1) PE20221778A1 (fr)
PH (1) PH12022551119A1 (fr)
PL (1) PL4073065T3 (fr)
PT (1) PT4073065T (fr)
RS (1) RS66721B1 (fr)
SI (1) SI4073065T1 (fr)
TW (1) TWI877268B (fr)
UA (1) UA128299C2 (fr)
WO (1) WO2021116055A1 (fr)
ZA (2) ZA202204675B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221027A1 (es) * 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
PT4073065T (pt) * 2019-12-10 2025-04-15 Hoffmann La Roche Novos derivados de metilquinazolinona
KR102904179B1 (ko) 2020-06-09 2025-12-26 어레이 바이오파마 인크. Braf-관련 질환 및 장애의 치료를 위한 4-옥소-3,4-다이하이드로퀸아졸린온 화합물
IL308748A (en) 2021-06-08 2024-01-01 C4 Therapeutics Inc Therapeutic agents for knockdown of mutant BRAF
KR102699226B1 (ko) * 2021-06-09 2024-08-27 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
MX2023014563A (es) * 2021-06-09 2024-02-08 Hoffmann La Roche Combinacion de un inhibidor de braf particular (interruptor de paradoja) y un antagonista de union al eje de pd-1 para su uso en el tratamiento de cancer.
CA3222612A1 (fr) * 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Nouvelles formes solides de (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
AU2022320304A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240105382A (ko) 2021-11-04 2024-07-05 에프. 호프만-라 로슈 아게 암 치료를 위한 퀴나졸리논 화합물의 신규한 용도
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
EP4618994A1 (fr) 2022-11-18 2025-09-24 F. Hoffmann-La Roche AG Composé de quinazolinone en tant qu'inhibiteur de braf pour le traitement d'un cancer solide avancé ou de métastases
JP2025541200A (ja) * 2022-12-15 2025-12-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん処置のための併用療法
AR131372A1 (es) * 2022-12-15 2025-03-12 Hoffmann La Roche Procedimiento para la preparación de un derivado de quinazolinona
WO2025008313A1 (fr) 2023-07-04 2025-01-09 F. Hoffmann-La Roche Ag Nouvelles formes solides de (3r)-n-[2-cyano-4-fluoro-3-(3-méthyl-4-oxo-quinazolin-6-yl)oxy-phényl]-3-fluoro-pyrrolidine-1-sulfonamide
WO2025108405A1 (fr) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 Préparation d'un dérivé de quinazolinone destiné à être utilisé en tant qu'inhibiteur de kinase, et son utilisation
WO2025153057A1 (fr) * 2024-01-17 2025-07-24 海思科医药集团股份有限公司 Composition pharmaceutique comprenant un inhibiteur de braf et utilisation d'une composition pharmaceutique en médecine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG10201608813PA (en) 2008-03-17 2016-12-29 Ambit Biosciences Corp Quinazoline derivatives as raf kinase modulators and methods of use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (fr) 2011-03-01 2012-09-07 Array Biopharma Inc. Sulfonamides hétérocycliques en tant qu'inhibiteurs de raf
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
BR112015005982A2 (pt) 2012-09-19 2017-07-04 Novartis Ag di-hidropirrolidino-pirimidinas como inibidores de quinase
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
CN113893253A (zh) 2015-05-22 2022-01-07 普莱希科公司 用于治疗braf-v600相关的疾病的plx-8394或plx-7904
RU2724345C2 (ru) 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
TWI748317B (zh) 2019-01-03 2021-12-01 美商建南德克公司 吡啶并－嘧啶酮與喋啶酮化合物及使用方法
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
PE20221027A1 (es) 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
PT4073065T (pt) 2019-12-10 2025-04-15 Hoffmann La Roche Novos derivados de metilquinazolinona
KR102904179B1 (ko) 2020-06-09 2025-12-26 어레이 바이오파마 인크. Braf-관련 질환 및 장애의 치료를 위한 4-옥소-3,4-다이하이드로퀸아졸린온 화합물
JP2023554062A (ja) 2020-12-18 2023-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規アリール－ピリド－ピリミジン－オン誘導体
CN116601147A (zh) 2020-12-18 2023-08-15 豪夫迈·罗氏有限公司 新喹唑啉酮衍生物
IL308748A (en) 2021-06-08 2024-01-01 C4 Therapeutics Inc Therapeutic agents for knockdown of mutant BRAF
AU2022403854B2 (en) 2021-12-08 2025-04-17 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide

Also Published As

Publication number Publication date
KR102836833B1 (ko) 2025-07-22
CO2022008968A2 (es) 2022-07-19
CL2022001529A1 (es) 2023-02-10
DK4073065T3 (da) 2025-04-22
ZA202204675B (en) 2022-12-21
TWI877268B (zh) 2025-03-21
WO2021116055A1 (fr) 2021-06-17
EP4073065B1 (fr) 2025-02-19
RS66721B1 (sr) 2025-05-30
US20240174621A1 (en) 2024-05-30
NZ787393A (en) 2025-07-25
CN114787156A (zh) 2022-07-22
PE20221778A1 (es) 2022-11-16
JP2022531609A (ja) 2022-07-07
IL316473A (en) 2024-12-01
US12116349B2 (en) 2024-10-15
SI4073065T1 (sl) 2025-06-30
KR20220110554A (ko) 2022-08-08
JP7108146B2 (ja) 2022-07-27
EP4483882A3 (fr) 2025-03-05
IL292161B2 (en) 2025-04-01
LT4073065T (lt) 2025-04-25
PH12022551119A1 (en) 2023-08-23
CR20220251A (es) 2022-07-11
CN118791472A (zh) 2024-10-18
AU2020403443A1 (en) 2022-05-12
HUE071148T2 (hu) 2025-08-28
IL292161A (en) 2022-06-01
ZA202206923B (en) 2024-10-30
CN114787156B (zh) 2024-07-26
IL292161B1 (en) 2024-12-01
AU2020403443B2 (en) 2023-02-23
PL4073065T3 (pl) 2025-05-19
UA128299C2 (uk) 2024-05-29
ES3023264T3 (en) 2025-05-30
BR112022011123A2 (pt) 2022-08-23
MX2022006783A (es) 2022-07-11
TW202504895A (zh) 2025-02-01
PT4073065T (pt) 2025-04-15
HRP20250418T1 (hr) 2025-06-06
AR122351A1 (es) 2022-09-07
CA3162883A1 (fr) 2021-06-17
TW202136245A (zh) 2021-10-01
US20220298119A1 (en) 2022-09-22
JP7802514B2 (ja) 2026-01-20
JP2022124458A (ja) 2022-08-25
EP4483882A2 (fr) 2025-01-01
FI4073065T3 (fi) 2025-04-16
EP4073065A1 (fr) 2022-10-19

Similar Documents

Publication Publication Date Title
MA58087B1 (fr) Nouveaux dérivés de méthylquinazolinone
MA52948B1 (fr) Composés
MA46337A (fr) Composé de pyridine
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA201892300A1 (ru) Макроциклические ингибиторы mcl1 для лечения рака
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA38472B1 (fr) Composé peptidique
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
MA39983B1 (fr) Dérivés de carboxamide
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
EA202192760A1 (ru) Трициклические соединения
FR3064634B1 (fr) Derives acryliques de 1 :4, 3 :6 dianhydrohexitol